SCHEMBL901430

SCHEMBL901430

Oc1c(Cc2ccc(Cl)c(Cl)c2)c(C2CC2)nc2ccnn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 5/20 0.47
CCR5 P51681 2/20 0.47
TSHR P16473 2/20 0.34
KCNN1 Q92952 1/20 0.34
KCNN2 Q9H2S1 1/20 0.34
KCNN3 Q9UGI6 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
RNASEH1 O60930 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4D Q08499 1/20 0.34
PLAT P00750 1/20 0.33
PDE10A Q9Y233 1/20 0.33
P2RX7 Q99572 1/20 0.32
DPP4 P27487 1/20 0.32
PDE2A O00408 1/20 0.32
SLC22A12 Q96S37 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902481 0.96 CCR2 (0.43) CCR2CCR5TSHRKCNN1KCNN2
SCHEMBL902384 0.90 CCR2 (0.38) CCR2CCR5PDE4BPDE4DPDE2A
SCHEMBL902260 0.90 MAPKAPK2 (0.40) CCR2CCR5PDE2A
SCHEMBL902565 0.86 CCR2 (0.35) CCR2CCR5PDE4BPDE4DPDE10A
SCHEMBL901755 0.86 MAPKAPK2 (0.39) CCR2CCR5PDE2A
SCHEMBL902501 0.86 CCR2 (0.38) CCR2CCR5KCNN1KCNN2KCNN3
SCHEMBL902809 0.85 CCR2 (0.49) CCR2CCR5KCNN1KCNN2KCNN3
SCHEMBL902240 0.84 CCR2 (0.35) CCR2CCR5DPP4PDE2A
SCHEMBL902593 0.84 CCR2 (0.41) CCR2CCR5KCNN1KCNN2KCNN3
SCHEMBL902334 0.83 CCR2 (0.41) CCR2KCNN1KCNN2KCNN3PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CCR2 1/4885CCR5 2/4885TSHR 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.